Pregled bibliografske jedinice broj: 514977
The prognostic value of tumor marker CYFRA 21-1 in NSCLC ; a three year longitudinal study on 500 patients
The prognostic value of tumor marker CYFRA 21-1 in NSCLC ; a three year longitudinal study on 500 patients // ATS 97th International Conference Abstract Book
New York (NY): American Thoracic Society (ATS), 2001. str. 485-485 (predavanje, nije recenziran, sažetak, znanstveni)
CROSBI ID: 514977 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
The prognostic value of tumor marker CYFRA 21-1 in NSCLC ; a three year longitudinal study on 500 patients
Autori
Pavićević, Radomir ; Bialk, Peter ; Bubanović, Gordana ; Krajna, Ana ; Samaržija, Miroslav ; Pavićević, Lukrecija
Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni
Izvornik
ATS 97th International Conference Abstract Book
/ - New York (NY) : American Thoracic Society (ATS), 2001, 485-485
Skup
ATS 97th International Conference
Mjesto i datum
San Francisco (CA), Sjedinjene Američke Države, 18.05.2001. - 23.05.2001
Vrsta sudjelovanja
Predavanje
Vrsta recenzije
Nije recenziran
Ključne riječi
CYFRA 21-1; lung cancer
Sažetak
The clinical application of cytokeratin marker CYFRA 21-1 was standardized on 2000 patients. In all patients the start value of CYFRA 21-1 was determined before therapy (Roche Diagnostics). Tumor marker CYFRA 21-1 was assessed longitudinally 1 to 36 months after the therapy, or before the next therapy. One to three months after the surgical treatment in 87% of the patients the marker values decreased to the healthy population level, depending on the therapy and TNM stage (p<0.0001). The …
Izvorni jezik
Engleski
Znanstvena područja
Biologija, Kliničke medicinske znanosti
POVEZANOST RADA
Ustanove:
Klinika za plućne bolesti "Jordanovac"
Profili:
Radomir Pavićević
(autor)
Lukrecija Pavićević
(autor)
Gordana Bubanović
(autor)
Ana Franjević
(autor)
Miroslav Samaržija
(autor)